Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ovascience Inc. (NASDAQ: OVAS).

Full DD Report for OVAS

You must become a subscriber to view this report.


Recent News from (NASDAQ: OVAS)

OvaScience, Inc. (OVAS) Merger with Millendo Therapeutics Conference Call (Transcript)
OvaScience, Inc. (OVAS) Merger with Millendo Therapeutics Conference Call August 09, 2018, 08:30 ET Executives Katie Lefeber - VP, Strategy and Operations Christopher Kroeger - CEO, President, Secretary & Director Julia Owens - CEO, President and Director, Millendo Therapeuti...
Source: SeekingAlpha
Date: August, 12 2018 01:34
OvaScience reports Q2 results
OvaScience (NASDAQ: OVAS ): Q2 EPS of -$0.22 More news on: OvaScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:45
OvaScience Reports Second Quarter 2018 Financial Results and Provides Strategic Alternatives Update
OvaScience SM (Nasdaq:OVAS), a company focused on developing novel treatments for women and couples struggling with infertility, today reported financial results for the second quarter ended June 30, 2018 and provided an update on its review of strategic alternatives. “Earlier to...
Source: Business Wire
Date: August, 09 2018 16:01
OvaScience to merge with privately held Millendo Therapeutics; OvaScience down 16%
Thinly traded OvaScience ( OVAS -16.7% ) agrees to merge with Millendo Therapeutics in an all-stock transaction, and the combined company is expected to operate as Millendo Therapeutics and trade on NASDAQ under the ticker "MLND" More news on: OvaScience, Inc., Merger & acquisition...
Source: SeekingAlpha
Date: August, 09 2018 13:21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of OvaScience, Inc. to Millendo Therapeutics, Inc. is Fair to Shareholders
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQGS:OVAS) stock  prior to August 9, 2...
Source: GlobeNewswire
Date: August, 09 2018 09:57
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
– Transaction to Advance Millendo’s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi Syndrome – – Companies to Host Conference Call to Discuss Transaction at 8:30 a.m. ET – OvaScience SM (Nasdaq:...
Source: Business Wire
Date: August, 09 2018 07:00
Free Technical Research on OPKO Health and Three More Biotech Equities
Stock Research Monitor: ONTX, OPHT, and OVAS LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respecti...
Source: ACCESSWIRE IA
Date: July, 17 2018 07:25
OvaScience reports Q1 results
OvaScience (NASDAQ: OVAS ): Q1 EPS of -$0.21 More news on: OvaScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 03 2018 16:45
OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
OvaScience SM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update. OvaScience is completing preclinical ...
Source: Business Wire
Date: May, 03 2018 16:01
OvaScience's (OVAS) CEO Christopher Kroeger on Q4 2017 Results - Earnings Call Transcript
OvaScience, Inc. (OVAS) Q4 2017 Earnings Conference Call March 15, 2018 4:30 PM ET Executives Jennifer Viera - Investor Relations Christopher Kroeger - Chief Executive Officer Jonathan Gillis - Senior Vice President, Finance Analysts Eliana Merle - Credit Suisse Presenta...
Source: SeekingAlpha
Date: March, 15 2018 19:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-070.73260.6930.7710.6911103,831
2018-12-060.74890.7440.840.7301629,871
2018-12-040.73240.750.78180.73414,113
2018-12-030.740.73310.740.7091271,601
2018-11-300.7183130.72980.7450.7097,845

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0710,66643,87124.3122Cover
2018-12-0618,50694,70319.5411Cover
2018-12-048,80056,82315.4867Cover
2018-12-0349,159128,17438.3533Short
2018-11-307,39221,38734.5631Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OVAS.


About Ovascience Inc. (NASDAQ: OVAS)

Logo for Ovascience Inc. (NASDAQ: OVAS)

OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company s patented technology is based on the discovery of egg precursor cells EggPCSM , which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENTSM aims to improve egg quality and increase the success of in vitro fertilization IVF . OvaScience s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine.

 

Contact Information

 

 

Current Management

  • Michelle Dipp / CEO, President
  • Alison Lawton / COO
  • Theresa McNeely / Chief Comm. Officer
  • Christopher Bleck / Corp. Commun.
  • Michael Silver / Senior Operations Manager

Current Share Structure

  • Market Cap: $33,241,480 - 05/11/2018
  • Issue and Outstanding: 35,758,907 - 04/30/2018

 


Recent Filings from (NASDAQ: OVAS)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 03 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 29 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 28 2018

 

 


Daily Technical Chart for (NASDAQ: OVAS)

Daily Technical Chart for (NASDAQ: OVAS)


Stay tuned for daily updates and more on (NASDAQ: OVAS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: OVAS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OVAS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of OVAS and does not buy, sell, or trade any shares of OVAS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/